Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AUPH

Aurinia Pharmaceuticals Inc

15.78

Jul 10 • 04:00PM ET -0.81 (-4.88%)

Healthcare Biotechnology Canada Mid NASD

Peers: MIRM PTCT RYTM VKTX BMRN INCY KRYS AXSM NBIX PHVS

| Held by: IWM IWO IBB VTWO FESM VHT AVSC PSC SPDW VFMO

Scroll to Statements

Index	RUT
Market Cap	2.03B
Enterprise Value	1.72B
Income	298.21M
Sales	298.30M
Book/sh	4.34
Cash/sh	2.95
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	128
IPO	Oct 20, 2003

P/E	7.29
Forward P/E	12.77
PEG	-
P/S	6.80
P/B	3.64
P/C	5.36
P/FCF	12.16
EV/EBITDA	11.51
EV/Sales	5.76
Quick Ratio	5.01
Current Ratio	5.55
Debt/Eq	0.12
LT Debt/Eq	0.09
Option/Short	Yes / Yes

EPS (ttm)	2.16
EPS next Y	1.24
EPS next Q	0.24
EPS this Y	-53.62%
EPS next Y	28.75%
EPS next 5Y	-4.55%
EPS past 3/5Y	- -
Sales past 3/5Y	28.30% 41.38%
EPS Y/Y TTM	696.05%
Sales Y/Y TTM	20.62%
EPS Q/Q	53.13%
Sales Q/Q	24.40%
Earnings	May 07 BMO
EPS/Sales Surpr.	28.21% 0.94%

Insider Own	12.11%
Insider Trans	12.37%
Inst Own	61.78%
Inst Trans	0.98%
ROA	48.54%
ROE	64.98%
ROIC	48.24%
Gross Margin	89.74%
Oper. Margin	43.58%
Profit Margin	99.97%
SMA20	-4.59%
SMA50	-1.24%
SMA200	6.09%
Trades

Shs Outstand	130.77M
Shs Float	113.03M
Short Float	8.48%
Short Ratio	6.42
Short Interest	9.59M
52W High	19.25 -18.03%
52W Low	8.28 90.58%
Volatility	4.45% 4.74%
ATR (14)	0.81
RSI (14)	45.38
Beta	1.42
Rel Volume	0.80
Avg Volume	1.49M
Volume	1,201,475

Perf Week	1.09%
Perf Month	0.00%
Perf Quarter	-1.13%
Perf Half Y	-1.50%
Perf YTD	-1.07%
Perf Year	76.71%
Perf 3Y	47.06%
Perf 5Y	25.44%
Perf 10Y	409.03%
Recom	2.00
Target Price	17.00
Prev Close	16.59
Price	15.78
Change	-4.88%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform	$16
Nov-07-25	Upgrade	Jefferies	Hold → Buy	$21
Nov-05-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$15
Jul-30-25	Resumed	H.C. Wainwright	Buy	$17
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight	$34 → $25
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform	$33 → $31
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform	$32
Jan-25-21	Reiterated	H.C. Wainwright	Buy	$30 → $35
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$34 → $28
Jun-17-20	Initiated	BTIG Research	Buy	$20
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy	$27
Dec-16-19	Reiterated	H.C. Wainwright	Buy	$25 → $32
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight	$14 → $16
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$9
Oct-30-17	Reiterated	H.C. Wainwright	Buy	$10 → $12
May-18-17	Reiterated	H.C. Wainwright	Buy	$12 → $10
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight	$14
Mar-22-17	Reiterated	FBR & Co.	Outperform	$9 → $11

Show Previous Ratings

Jul-06-26 08:00AM	Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis (Business Wire)
Jun-12-26 06:47PM	Aurinia Pharmaceuticals and Four More Stocks See Activist Action (Barrons.com)
Jun-04-26 07:00AM	LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death (Business Wire)
May-19-26 08:30AM	Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences (Newsfile)
May-07-26 08:06AM	Aurinia: Q1 Earnings Snapshot (Associated Press) -6.80%
11:00AM	Loading…
Mar-30-26 11:00AM	United rises on IPF results; Biogen scores positive lupus data and an approval (BioPharma Dive)
11:00AM	United rises on IPF data; Biogen scores positive lupus data and an approval (BioPharma Dive)
Mar-23-26 12:13PM	Mutiny At Aurinia Pharmaceuticals? Biotech Soars On C-Suite Shake-Up. (Investor's Business Daily)
11:00AM	MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition (Business Wire)
08:00AM	Aurinia Announces Management Transition (Business Wire)
Mar-13-26 08:29PM	W.R. Berkley, Ziff Davis, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-04-26 01:35PM	Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77 (Investor's Business Daily) +6.29%
Mar-01-26 04:27AM	Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025 (Insider Monkey)
Feb-26-26 08:03PM	Aurinia Pharmaceuticals Inc. Q4 2025 Earnings Call Summary (Moby)
04:10PM	Aurinia Pharmaceuticals Inc (AUPH) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
04:06PM	Loading…
04:06PM	Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets (Benzinga)
12:06PM	Aurinia Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:15AM	Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:12AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress (Business Wire)
Feb-25-26 12:15PM	United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates (Zacks)
Feb-24-26 01:14PM	CRISPR Therapeutics Stock Sees RS Rating Rise To 73 (Investor's Business Daily)
01:02PM	Xenon Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Feb-19-26 06:00AM	Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 (Business Wire)
Feb-11-26 05:10PM	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
Feb-06-26 02:03PM	This Pharma Stock With Earnings Seen Soaring 1,854% Forms Bullish Base (Investor's Business Daily)
Jan-13-26 02:20PM	Moderna Stock Gets Healthy Relative Strength Rating Jump (Investor's Business Daily)
Dec-26-25 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-10-25 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
Dec-05-25 12:00PM	What Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now? (Zacks)
10:15AM	Loading…
Dec-02-25 10:15AM	Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options (Zacks)
Nov-27-25 09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue? (Zacks)
Nov-24-25 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-18-25 02:19PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-17-25 01:17PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-07-25 12:20PM	Can Aurinia (AUPH) Run Higher on Rising Earnings Estimates? (Zacks)
Nov-04-25 04:05PM	Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings Call Highlights: Strong Lupkynis Sales and ... (GuruFocus.com) +8.35%
07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
06:11AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress (Business Wire)
Nov-03-25 06:00AM	Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 (Business Wire)
05:00AM	Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark (BioPharma Dive)
04:49AM	Stocks to Watch Monday: Berkshire Hathaway, Onsemi, Palantir (The Wall Street Journal)
Nov-02-25 07:59PM	FDA Official Steps Down, Sued by Drugmaker (The Wall Street Journal)
Oct-16-25 01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
Oct-15-25 06:00AM	Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 (Business Wire)
Oct-08-25 01:05PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
Oct-01-25 06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)
Sep-30-25 12:34PM	Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-29-25 08:27PM	Aurinia Responds to Now Retracted LinkedIn Post (Business Wire) -15.83%
03:19PM	Cytokinetics Stock Scores RS Rating Jump To 83 (Investor's Business Daily)
Sep-17-25 01:45PM	Oric Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-08-25 02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Sep-03-25 02:02PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily)
Aug-27-25 01:57PM	KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily)
Aug-07-25 02:00PM	Supernus Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Aug-04-25 12:00PM	Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know (Zacks) +9.15%
Aug-01-25 05:01AM	Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +13.47%
Jul-31-25 07:15AM	Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates (Zacks)
06:13AM	Aurinia: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 (Business Wire)
Jul-22-25 06:00AM	Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 (Business Wire)
Jul-02-25 08:48AM	Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options (Zacks)
Jun-30-25 06:00AM	Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) (Business Wire)
Jun-29-25 05:00PM	Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 (Business Wire)
Jun-27-25 08:56AM	Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
May-30-25 08:46AM	Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? (Zacks)
May-22-25 06:00AM	New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis (Business Wire)
May-13-25 09:24AM	Company News for May 13, 2025 (Zacks)
03:03AM	Aurinia Pharmaceuticals Inc (AUPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-12-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
06:07AM	Aurinia: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 (Business Wire)
May-05-25 06:00AM	Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 (Business Wire)
Apr-30-25 06:00AM	Glass Lewis Recommends That Aurinia Shareholders Vote FOR All Proposals at 2025 Annual General Meeting (Business Wire)
Apr-29-25 06:00AM	ISS Recommends That Aurinia Shareholders Vote FOR All Proposals at 2025 Annual General Meeting (Business Wire)
Apr-26-25 10:54AM	Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (Seeking Alpha)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 04:05PM	Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting (Business Wire)
09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
Mar-25-25 10:41AM	Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-07-25 04:47PM	Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-04-25 01:14PM	Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? (Zacks)
Feb-28-25 02:13AM	Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +5.30%
Feb-27-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates (Zacks) -5.03%
06:28AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress (Business Wire)
Feb-25-25 12:31PM	Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey)
Feb-20-25 04:05PM	Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 (Business Wire)
Jan-22-25 12:00PM	Aurinia (AUPH) Upgraded to Buy: Here's Why (Zacks)
Dec-10-24 08:30AM	Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options (Zacks) +14.35%
Nov-18-24 05:53PM	Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis (Business Wire)
Nov-15-24 06:00AM	Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS in Managing LN at American College of Rheumatology Convergence 2024 (Business Wire)
Nov-14-24 06:00AM	Aurinia to Participate in Jefferies London Healthcare Conference (Business Wire)
Nov-08-24 10:30AM	Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets (Pharmaceutical Technology)
06:37AM	Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring (TipRanks)
02:12AM	Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-07-24 07:40AM	Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates (Zacks) +10.90%

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Chairman & CEOMr. Kevin C. Tang

Chief Legal OfficerMr. Stephen P. Robertson

ConsultantMr. Peter S. Greenleaf M.B.A.

Chief Financial OfficerMr. Michael S. Hearne CPA

Chief Operating OfficerMr. Ryan Cole

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GREGORY KEENAN	Former Affiliate	Jun 05 '26	Proposed Sale	16.52	9,593	158,490		Jun 05 04:27 PM
GREGORY KEENAN	Former Affiliate	Jun 04 '26	Proposed Sale	16.34	25,000	408,435		Jun 04 04:12 PM
TANG KEVIN	Chief Executive Officer	Jun 01 '26	Buy	15.28	343,620	5,250,520	12,838,101	Jun 02 09:54 PM
TANG KEVIN	Chief Executive Officer	May 29 '26	Buy	15.31	264,981	4,056,951	12,494,481	Jun 02 09:54 PM
TANG KEVIN	Chief Executive Officer	Jun 02 '26	Buy	15.28	206,005	3,147,756	13,044,106	Jun 02 09:54 PM
GREGORY KEENAN	Officer	Jun 02 '26	Proposed Sale	15.39	25,000	384,750		Jun 02 04:13 PM
PETER GREENLEAF	Former Affiliate	May 11 '26	Proposed Sale	15.84	3,136,201	49,677,424		May 11 04:11 PM
MATTHEW MAXWELL DONLEY	Former Affiliate	May 11 '26	Proposed Sale	15.84	717,688	11,368,178		May 11 04:10 PM
JOSEPH MILLER	Former Affiliate	May 11 '26	Proposed Sale	15.84	500,503	7,927,968		May 11 04:07 PM
TANG KEVIN	Director	Feb 27 '26	Buy	13.99	516,439	7,226,535	11,845,939	Mar 03 05:35 PM
TANG KEVIN	Director	Mar 02 '26	Buy	14.26	199,353	2,842,833	12,045,292	Mar 03 05:35 PM
TANG KEVIN	Director	Mar 03 '26	Buy	14.22	184,208	2,619,438	12,229,500	Mar 03 05:35 PM
TANG KEVIN	Director	Aug 01 '25	Buy	10.12	1,000,000	10,120,000	11,029,500	Aug 05 05:31 PM
TANG KEVIN	Director	Aug 05 '25	Buy	11.68	200,000	2,336,000	11,329,500	Aug 05 05:31 PM
TANG KEVIN	Director	Aug 04 '25	Buy	11.34	100,000	1,134,000	11,129,500	Aug 05 05:31 PM
Keenan Greg	Chief Medical Officer	Aug 01 '25	Sale	10.50	20,000	210,000	133,484	Aug 05 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AUPH

Aurinia Pharmaceuticals Inc

Upgrade your Finviz experience